Loading clinical trials...
Loading clinical trials...
A Prospective Study of Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed and Refractory Primary Central Nervous System Lymphoma.
Conditions
Interventions
Induction therapy-2 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor)
Consolidation therapy with ASCT after TB (Thiotepa plus Busulfan) preconditioning
+3 more
Locations
1
China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Start Date
January 2, 2025
Primary Completion Date
January 2, 2030
Completion Date
January 2, 2032
Last Updated
July 20, 2025
NCT07198087
NCT04688151
NCT06714370
NCT04253496
NCT00710151
Lead Sponsor
The First Affiliated Hospital of Soochow University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions